BCRX Q4 2019 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$40M+1355.7% YoY

Gross Profit

$37M93.5% margin

Operating Income

-$109,000-0.3% margin

Net Income

-$3M-6.6% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

+2138.0%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$11M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$175M

Total Liabilities

$137M

Stockholders' Equity

$38M

Cash & Equivalents

$114M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$40M	$3M	+1355.7%
Gross Profit	$37M	$3M	+1297.3%
Operating Income	-$109,000	-$25M	+99.6%
Net Income	-$3M	-$27M	+90.4%

Revenue Segments

Collaborative and Other Research and Development

$21M54%

Product

$16M39%

Royalty

$3M7%